Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabhalta
Pharma
Novartis touts trial win, nabs priority review for Fabhalta
Fabhalta led to a statistically significant 38.3% reduction of proteinuria (protein in the urine) in patients with IgA nephropathy, Novartis said.
Eric Sagonowsky
Apr 15, 2024 4:22pm
AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod
Apr 1, 2024 11:48am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am
FDA grants Calliditas full nod for kidney disease drug Tarpeyo
Dec 20, 2023 5:24pm
Novartis shows strong Fabhalta results in another blood disorder
Dec 11, 2023 11:20am
Novartis gains first FDA approval for touted blood disorder drug
Dec 6, 2023 11:02am